Evaluation of Short-term Safety of COVID-19 Vaccines in Patients with Multiple Sclerosis from Latin America

Overview

Journal Mult Scler J Exp Transl Clin

Date 2021 Dec 6

PMID 34868630

Citations 10

Authors

Ricardo Alonso

Anibal Chertcoff

Felisa Del V Leguizamon

Lorna Galleguillos Goiry

Maria B Eizaguirre

Roberto Rodriguez

Marta Sosa

Susana Carballido

Veronica Cruchet

Agnes de Jong-Martis

Susana Giachello

Paula Henestroza

Flavia Ferrandina

Johana Bauer

Adriana Carra

Berenice A Silva

Affiliations

Soon will be listed here.

Abstract

Background: To date, there are no data available on the safety of COVID-19 vaccines in Latin American patients with Multiple Sclerosis (MS).

Objective: Characterize safety of COVID-19 vaccines in Latin American (LATAM) patients with Multiple Sclerosis (pwMS).

Methods: A cross-sectional study between February 1, 2021, and April 30, 2021. Individuals with MS from LATAM countries were invited to participate in a self-administered web-based survey, through MS patient organizations from the region.

Results: 393 vaccinated pwMS from 10 different Latin American countries were included. The vaccines administered were: inactivated virus vaccines (IVV) in 38.2% of patients, adenovirus vector vaccines (AdV) in 48.8% and mRNA vaccines 13%. All patients received at least one dose of any of the COVID-19 vaccines and 123 (31.3%) declared receiving a second dose. Mean (SD) age 41.5 (11.8) years, 82.4% female, MS disease duration: 8.4 (8.2) years. No serious adverse events were reported with any of the COVID-19 vaccines after either the first or second dose. A lower frequency of adverse events was found with IVV (22%) in comparison with AdV (46.4%) and mRNA (35.3%) ( < 0.01). Five participants reported having an MS relapse after IVV first dose.

Conclusion: COVID-19 vaccines applied in LATAM proved safe for MS patients.

Citing Articles

Safety of COVID-19 Vaccines in Patients With Multiple Sclerosis: A Cross-Sectional Study From a Tertiary Rehabilitation Center in Saudi Arabia.

Mohamed S, Elkarim M, Al-Jaberi S Cureus. 2025; 16(12):e75889.

PMID: 39822416 PMC: 11737604. DOI: 10.7759/cureus.75889.

Humoral immune response and safety of Sars-Cov-2 vaccine in people with multiple sclerosis.

Hamzavi S, Bahrololoom R, Saeb S, Marandi N, Hosseini M, Hesam Abadi A BMC Immunol. 2024; 25(1):35.

PMID: 38898409 PMC: 11186195. DOI: 10.1186/s12865-024-00628-w.

Risk of flare or relapse in patients with immune-mediated diseases following SARS-CoV-2 vaccination: a systematic review and meta-analysis.

Shabani M, Shobeiri P, Nouri S, Moradi Z, Amenu R, Mehrabi Nejad M Eur J Med Res. 2024; 29(1):55.

PMID: 38229141 PMC: 10792904. DOI: 10.1186/s40001-024-01639-4.

Occurrence and Risk Factors of Relapse Activity after Vaccination against COVID-19 in People with Multiple Sclerosis: 1-Year Follow-Up Results from a Nationwide Longitudinal Observational Study.

Fneish F, Frahm N, Peters M, Ellenberger D, Haas J, Lobermann M Vaccines (Basel). 2023; 11(12).

PMID: 38140262 PMC: 10747540. DOI: 10.3390/vaccines11121859.

Short-term safety of inactivated SARS-Cov-2 vaccines in Chinese patients with central nervous system inflammatory demyelinating diseases.

Zhao D, Zhang W, Ma X, Zhao R, Yao L, Lu J Vaccine X. 2023; 15:100388.

PMID: 37767538 PMC: 10520881. DOI: 10.1016/j.jvacx.2023.100388.

References

Alonso R, Silva B, Garcea O, Diaz P, Dos Passos G, Ramirez Navarro D . COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America: COVID-19 in MS and NMOSD patients in LATAM. Mult Scler Relat Disord. 2021; 51:102886. PMC: 7937038. DOI: 10.1016/j.msard.2021.102886. View

Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z . Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA. 2020; 324(10):951-960. PMC: 7426884. DOI: 10.1001/jama.2020.15543. View

Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B . Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021; 384(23):2187-2201. PMC: 8220996. DOI: 10.1056/NEJMoa2101544. View

Folegatti P, Ewer K, Aley P, Angus B, Becker S, Belij-Rammerstorfer S . Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249):467-478. PMC: 7445431. DOI: 10.1016/S0140-6736(20)31604-4. View

Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P . Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021; 14:17562864211012835. PMC: 8072850. DOI: 10.1177/17562864211012835. View

Farez M, Correale J . Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. Arch Neurol. 2011; 68(10):1267-71. DOI: 10.1001/archneurol.2011.131. View

Achiron A, Dolev M, Menascu S, Zohar D, Dreyer-Alster S, Miron S . COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021. Mult Scler. 2021; 27(6):864-870. PMC: 8114441. DOI: 10.1177/13524585211003476. View

Allen-Philbey K, Stennett A, Begum T, Johnson A, Dobson R, Giovannoni G . Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis. Mult Scler Relat Disord. 2021; 52:103028. PMC: 8129799. DOI: 10.1016/j.msard.2021.103028. View

Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416. PMC: 7787219. DOI: 10.1056/NEJMoa2035389. View

10.

Cucinotta D, Vanelli M . WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020; 91(1):157-160. PMC: 7569573. DOI: 10.23750/abm.v91i1.9397. View

11.

Chertcoff A, Bauer J, Silva B, Aldecoa M, Eizaguirre M, Rodriguez R . Changes on the health care of people with multiple sclerosis from Latin America during the COVID-19 pandemic. Mult Scler Relat Disord. 2021; 54:103120. DOI: 10.1016/j.msard.2021.103120. View

12.

Learmonth Y, Motl R, Sandroff B, Pula J, Cadavid D . Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol. 2013; 13:37. PMC: 3651716. DOI: 10.1186/1471-2377-13-37. View

13.

Colmegna I, Valerio V, Gosselin-Boucher V, Lacoste G, Labbe S, Lavoie K . Barriers and facilitators to influenza and pneumococcal vaccine hesitancy in rheumatoid arthritis: a qualitative study. Rheumatology (Oxford). 2021; 60(11):5257-5270. DOI: 10.1093/rheumatology/keab471. View

14.

Sormani M, Inglese M, Schiavetti I, Carmisciano L, Laroni A, Lapucci C . Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine. 2021; 72:103581. PMC: 8456129. DOI: 10.1016/j.ebiom.2021.103581. View

15.

Apostolidis S, Kakara M, Painter M, Goel R, Mathew D, Lenzi K . Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med. 2021; 27(11):1990-2001. PMC: 8604727. DOI: 10.1038/s41591-021-01507-2. View

16.

Logunov D, Dolzhikova I, Zubkova O, Tukhvatullin A, Shcheblyakov D, Dzharullaeva A . Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020; 396(10255):887-897. PMC: 7471804. DOI: 10.1016/S0140-6736(20)31866-3. View

17.

Huttner A, Eperon G, Lascano A, Roth S, Schwob J, Siegrist C . Risk of MS relapse after yellow fever vaccination: A self-controlled case series. Neurol Neuroimmunol Neuroinflamm. 2020; 7(4). PMC: 7217657. DOI: 10.1212/NXI.0000000000000726. View

18.

Etemadifar M, Akhavan Sigari A, Sedaghat N, Salari M, Nouri H . Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient. Hum Vaccin Immunother. 2021; 17(10):3481-3483. PMC: 8437516. DOI: 10.1080/21645515.2021.1928463. View

19.

Farez M, Correale J . Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J Neurol. 2011; 258(7):1197-206. DOI: 10.1007/s00415-011-5984-2. View

20.

S G, S L, C Z, A N, M F, L M . Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience. J Neurol. 2021; 269(1):39-43. PMC: 8241206. DOI: 10.1007/s00415-021-10663-x. View